Danaher Corporation $DHR Shares Newly Acquired by Ables Iannone Moore & Associates Inc.

Ables Iannone Moore & Associates Inc. acquired a new position in shares of Danaher Corporation (NYSE:DHR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,362 shares of the conglomerate’s stock, valued at approximately $1,853,000. Danaher comprises about 1.0% of Ables Iannone Moore & Associates Inc.’s portfolio, making the stock its 20th biggest holding.

Other large investors have also recently bought and sold shares of the company. Main Street Group LTD acquired a new stake in Danaher in the 1st quarter valued at $25,000. N.E.W. Advisory Services LLC bought a new stake in Danaher during the second quarter worth about $25,000. Hilton Head Capital Partners LLC acquired a new position in Danaher during the fourth quarter valued at approximately $27,000. Clal Insurance Enterprises Holdings Ltd grew its stake in Danaher by 71.6% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 53 shares in the last quarter. Finally, Evolution Wealth Management Inc. grew its stake in Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 104 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR traded down $3.48 during mid-day trading on Tuesday, reaching $217.73. 1,774,393 shares of the company were exchanged, compared to its average volume of 4,452,227. The stock has a market capitalization of $153.06 billion, a P/E ratio of 38.67, a P/E/G ratio of 2.67 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The company’s 50-day simple moving average is $209.69 and its 200-day simple moving average is $193.88. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the prior year, the business earned $0.77 EPS. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is 28.42%.

Analyst Ratings Changes

Several equities analysts recently weighed in on DHR shares. The Goldman Sachs Group raised their target price on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Guggenheim boosted their price objective on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. UBS Group assumed coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target for the company. Finally, TD Cowen dropped their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $234.09.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.